AMRX

AMRX

USD

Amneal Pharmaceuticals Inc. Class A Common Stock

$11.350+0.340 (3.088%)

Echtzeitkurs

Healthcare
Drug Manufacturers - Specialty & Generic
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$11.010

Hoch

$11.400

Tief

$10.940

Volumen

3.47M

Unternehmensfundamentaldaten

Marktkapitalisierung

3.6B

Branche

Drug Manufacturers - Specialty & Generic

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

1.66M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $6.685Aktuell $11.350Hoch $11.4

Ähnliche Nachrichten

Analyst Upgrades

Piper Sandler Reiterates Overweight on Amneal Pharmaceuticals, Raises Price Target to $13

Piper Sandler analyst David Amsellem reiterates Amneal Pharmaceuticals with a Overweight and raises the price target from $11 to $13.

Mehr anzeigen
Piper Sandler Reiterates Overweight on Amneal Pharmaceuticals, Raises Price Target to $13
GlobeNewswire

Amneal Reports Third Quarter 2025 Financial Results

‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER,

Mehr anzeigen
Amneal Reports Third Quarter 2025 Financial Results
GlobeNewswire

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has tentatively approved the Company's

Mehr anzeigen